| | | |   | | | | By Ed Silverman A report finds the NIH failed to ensure that results of roughly half of clinical trials funded by the agency were reported. Read More | | By Matthew Herper Wikimedia Commons The data, though inarguably positive, will lead to discussion about Ayvakit's safety and efficacy as well as Blueprint’s pricing strategy. Read More | | By Allison DeAngelis STAT Dudley enjoys working across the health care space — he can talk about everything from insurance claims to CRISPR gene editing. Read More | | Sponsor content by STAT Leading JAMA Through Turmoil New JAMA editor-in-chief, health equity advocate Kirsten Bibbins-Domingo, takes the virtual stage on September 20. She'll share how she plans to steer the prestigious publication through recent turbulence and chart a new journey forward. Join the conversation. | | By Tara Bannow Adobe Hospitals that merge under COPAs tend to eventually break free of those controls and raise prices substantially, new research finds. Read More | | By Angus Chen Molly Ferguson for STAT With the right synthetic biomarkers, scientists may be able to find cancers earlier, tailor treatment and track progress. Read More | |
No comments